Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) treatment for first-line therapy of patients with CLL with mutated IGHV and without deletion 17p

Category Primary study
JournalClinical Lymphoma, Myeloma and Leukemia
Year 2017
This article has no abstract
Epistemonikos ID: 58e15b5afd0ff82219f4d23cb5aeb775158901f8
First added on: Feb 08, 2025